Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rovaris, M.
Right arrow Articles by Filippi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rovaris, M.
Right arrow Articles by Filippi, M.
Related Collections
Right arrow All Imaging
Right arrow MRI
Right arrow Multiple sclerosis

Neurology 2002;59:1429-1432
© 2002 American Academy of Neurology
Brief Communications

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

M. Rovaris, MD, M. Codella, MD, L. Moiola, MD, A. Ghezzi, MD, M. Zaffaroni, MD, G. Mancardi, MD, E. Capello, MD, F. Sardanelli, MD, G. Comi, MD and M. Filippi, MD

From the Neuroimaging Research Unit (Drs. Rovaris, Codella, and Filippi) and Clinical Trials Unit (Drs. Moiola and Comi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan; Multiple Sclerosis Center (Drs. Ghezzi and Zaffaroni), Ospedale di Gallarate; and Department of Neurological Sciences (Drs. Mancardi, Capello, and Sardanelli), University of Genoa, Italy.

Address correspondence and reprint requests to Dr. Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, via Olgettina 60, 20132 Milan, Italy; e-mail: filippi.massimo{at}hsr.it

This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.




This article has been cited by other articles:


Home page
 NeurologyHome page
Y. Zhao, A. Traboulsee, A. J. Petkau, and D. Li
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1092 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. P. Lisak
Neurodegeneration in multiple sclerosis: Defining the problem
Neurology, May 29, 2007; 68(22_suppl_3): S5 - S12.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Horani, N. Muhanna, O. Pappo, A. Melhem, C. E. Alvarez, S. Doron, W. Wehbi, K. Dimitrios, S. L. Friedman, and R. Safadi
Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis
Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G628 - G638.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M P Sormani, P Bruzzi, G Comi, and M Filippi
The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis
Multiple Sclerosis, August 1, 2005; 11(4): 447 - 449.
[Abstract] [PDF]